Why the study?
Does telmisartan improve the regression of left ventricular hypertrophy compared to atenolol in patients with essential hypertension?
Population
48 patients with essential hypertension and left ventricular hypertrophy from a single center in India.
Comparison
Telmisartan 80 mg oral once daily for 6 months vs Atenolol 50 mg oral once daily for 6 months
Design
Cohort
Follow-up
6 months
Authors
Loading...
Telmisartan was associated with greater LVMI reduction than atenolol; leaves open ARB preference for LVH regression pending randomized trials.
Does telmisartan improve the regression of left ventricular hypertrophy compared to atenolol in patients with essential hypertension?
Telmisartan is superior to atenolol in achieving regression of left ventricular hypertrophy in patients with essential hypertension.
Kumar Haraprasad Misra (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: